Biological response modifiers: current use and future prospects in cancer therapy

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Biological response modifiers (BRMs) have shown significant success in cancer treatment by enhancing the host immune system.
• BRMs encompass a range of agents, including interferons, interleukins, monoclonal antibodies, antiangiogenic agents, and tumor vaccines.
• These agents can provide active or passive immunity, or target specific cancer pathways.

Purpose of the Study:

• To review the current applications of biological response modifiers in cancer treatment.
• To discuss the future development and potential of cancer immunotherapy utilizing BRMs.
• To highlight the role of BRMs as standalone therapy or as adjuncts to chemotherapy.

Main Methods:

• A literature search was conducted using PubMed.
• The search terms "Biological response modifiers in cancer" were utilized.
• Relevant citations were screened for inclusion in the review.

Main Results:

• BRMs are increasingly utilized in cancer treatment, offering diverse mechanisms of action.
• Agents like interferons, interleukins, and monoclonal antibodies modulate immune responses.
• Other BRMs, including tyrosine kinase inhibitors and tumor vaccines, represent novel therapeutic strategies.

Conclusions:

• Biological response modifiers represent a cornerstone of modern cancer immunotherapy.
• Continued research into BRMs promises advancements in personalized cancer treatment.
• BRMs offer a promising avenue for improving patient outcomes in oncology.